| 2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5, 6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from … J Ragaz, M Lippman, M Van Rijn, A Brodie, D Jelovac, T Nielsen, ... Breast Cancer Research and Treatment 79, 278-278, 2003 | 1 | 2003 |
| 2008 Niday Perinatal Database quality audit: report of a quality assurance project S Dunn, J Bottomley, A Ali, M Walker Health Promotion and Chronic Disease Prevention in Canada 32 (1), 2011 | 76 | 2011 |
| 4.“Biphasic” histology is associated with the non-WNT/SHH molecular subtype of medulloblastoma C Dunham, C Foster, J Triscott, S Dunn Canadian Journal of Neurological Sciences 42 (S2), S2-S3, 2015 | | 2015 |
| 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6, 7, 8, 9-tetrahydropyrido [3', 2': 4, 5] pyrrolo [1, 2-A] pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase-(RSK-) hæmmere til … SE Dunn, A JAYANTHAN, JR Nagireddy, S Annedi, DJH Van, ... | | 2021 |
| A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer SE Dunn, M Ehrlich, NJH Sharp, K Reiss, G Solomon, R Hawkins, ... Cancer research 58 (15), 3353-3361, 1998 | 374 | 1998 |
| A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic … M Beeram, JS Wang, P Chalasani, L Mina, A Patnaik, MR Pambid, ... CANCER RESEARCH 81 (4), 2021 | 1 | 2021 |
| A Novel Therapeutic Approach of Suicide Gene/prodrug Therapy by Human Tumor-tropic Genetically Engineered Stem Cells expressing Suicide Genes to Selectively Target Ovarian and … KIM Ki-Yon, PCK LEUNG, EB JEUNG, C Kyung-Chul 한국실험동물학회 학술발표대회 논문집, 212-212, 2009 | | 2009 |
| Abstract A037: YB-1 transforms mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer AH Davies, KM Reipas, N Firmino, AL Stratford, R Berns, A Fotovati, ... Molecular Cancer Research 11 (10_Supplement), A037-A037, 2013 | | 2013 |
| Abstract B065: The RSK/YB-1 pathway represents an opportunity for targeting TNBC and holds promise of treating metastases AL Stratford, R Berns, P So, MR Pambid, F Abbas, S Abu-Ali, K Hu, ... Molecular Cancer Research 11 (10_Supplement), B065-B065, 2013 | | 2013 |
| Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain A Fotovati, S Abu-Ali, PS Wang, L Deleyrolle, C Lee, J Tricott, J Chen, ... Cancer Research 71 (8_Supplement), LB-101-LB-101, 2011 | | 2011 |
| Abstract LB-214: Common genomic alterations in malignant peripheral nerve sheath tumors augment Aurora A activity and sensitize tumors to aurora kinase inhibitors. P Mohan, J Castellsague, J Jiang, K Allen, H Chen, O Nemirovsky, ... Cancer Research 73 (8_Supplement), LB-214-LB-214, 2013 | | 2013 |
| Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC) SE Dunn, A Jayanthan, M Huynh, E Flahive, MR Pambid, A Dorr, G Los Cancer Research 80 (4_Supplement), P3-10-10-P3-10-10, 2020 | 6 | 2020 |
| Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor JS Wang, M Beeram, P Chalasani, L Mina, RA Shatsky, S Hurvitz, ... Cancer Research 83 (5_Supplement), P4-01-16-P4-01-16, 2023 | | 2023 |
| Abstract PO3-29-04: Patient selection for high RSK2 expression is key for achieving improved PFS in metastatic breast cancer in the PMD-026 Phase 1/1b study S Dunn, J Wang, H Han, R Wesolowski, A Patnaik, S Bahadur, ... Cancer Research 84 (9_Supplement), PO3-29-04-PO3-29-04, 2024 | | 2024 |
| Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor … M Beeram, JS Wang, P Chalasani, L Mina, A Patnaik, MR Pambid, ... Cancer Research 81 (4_Supplement), PS11-33-PS11-33, 2021 | | 2021 |
| Abstract# 3063: YB-1 induces CD44 and CD49f thereby promoting the capacity for tumor initiation K To, K Reipas, K Hu, A Fotovati, A Raouf, C Eaves, S Dunn Cancer Research 69 (9_Supplement), 3063-3063, 2009 | | 2009 |
| Abstracts from the 2011 BNOS Conference, June 29–July 1, 2011, Homerton College, Cambridge A Fotovati, S Abu-Ali, P Wang, L Deleyrolle, C Lee, J Triscott, J Chen, ... Neuro-oncology 13 (Suppl 2), ii1-ii14, 2011 | | 2011 |
| Abstracts from the Thirteenth International Symposium on Pediatric Neuro-Oncology: June 29–July 2, 2008: Chicago, Illinois, USA D Birks, A Donson, S Mcnatt, N Foreman, M Handler, H Oka, K Fujii, ... Neuro-oncology 10 (3), 370-515, 2008 | | 2008 |
| Abstracts from the Thirteenth International Symposium on Pediatric Neuro‐Oncology: June 29–July 2, 2008: Chicago, Illinois, USA M Matsutani Neuro‐oncol 10, 370-515, 2008 | 1 | 2008 |
| Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2 … J Ragaz, K Miller, S Badve, Y Dayachko, S Dunn, T Nielsen, A Brodie, ... ASCO Annual Meeting Proceedings 22 (14_suppl), 524-529, 2004 | 17* | 2004 |
